Cell – Page 2 – Talk Bio

Imvax Shares Positive Phase 2b Data for IGV-001 Glioblastoma Treatment and Plans FDA Meeting

2 months ago talkbio0Tagged Clinical Trials, Glioblastoma, IGF-1R Antisense Oligodeoxynucleotide-treated Autologous Glioma Cells IGV-001, Immunotherapy, Imvax, meeting, Overall Survival, United States Food and Drug Administration

Imvax; IGV-001; glioblastoma; Phase 2b trial; overall survival; FDA meeting; immunotherapy; clinical trial; glioblastoma treatment

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial on December 3, 2025

2 months ago talkbio0Tagged clinical trial update, Corporate, Effectiveness, loncastuximab tesirine, LOTIS-7, Phase 1b Trial, Safety, therapeutic autologous dendritic cells, Zynlonta

ADC Therapeutics; LOTIS-7; clinical trial update; ZYNLONTA; Phase 1b trial; loncastuximab tesirine; safety; efficacy; corporate webcast

Whitehawk Therapeutics Appoints Margaret Dugan as Chief Medical Officer

2 months ago talkbio0Tagged Chief Medical Officer, Chronic multifocal osteomyelitis, Clinical Trials, Dracen Pharmaceuticals, Drug Development, Margaret Dugan, Neoplasms, Novartis, Schrödinger, therapeutic autologous dendritic cells, Whitehawk Therapeutics

Whitehawk Therapeutics; Margaret Dugan; Chief Medical Officer; CMO; oncology; ADC; drug development; clinical trials; Novartis; Dracen Pharmaceuticals; Schrödinger

Aspen Neuroscience Secures $115 Million Series C to Advance Parkinson’s Cell Therapy; IPO Considered for 2026

2 months ago talkbio0Tagged Aspen, Bach Flower Essence, Autologous (qualifier value), Cell Therapy, Clinical Trials, Induced Pluripotent Stem Cells, IPO, manufacturing scale-up, Neuroscience discipline, Parkinson 's disease, plans, Regenerative Medicine, Series C financing

Aspen Neuroscience; Series C financing; Parkinson’s disease; cell therapy; ANPD001; autologous iPSC; clinical trials; manufacturing scale-up; IPO plans; regenerative medicine

GSK and LTZ Therapeutics Announce $50M Partnership to Develop First-in-Class Myeloid Cell Engagers for Cancer

2 months ago talkbio0Tagged Biotechnology, engagers, hematologic cancers, Immunotherapy, letrozole, Myeloid Progenitor Cells, Neoplasms, preclinical programs, SmithKline Beecham, Solid Neoplasm, strategic collaboration, upfront

GSK; LTZ Therapeutics; myeloid cell engagers; oncology; hematologic cancers; solid tumors; immunotherapy; strategic collaboration; biotechnology; $50 million upfront; preclinical programs

Solve Therapeutics Raises $120M to Advance Next-Generation ADCs for Solid Tumors

2 months ago talkbio0Tagged Antibody-Drug Conjugates, Clinical Trials, CloakLink linker technology, Merck, Neoplasms, SLV-154, SLV-324, Solid Neoplasm, Solve Therapeutics, therapeutic autologous dendritic cells, venture capital, Yosemite

Solve Therapeutics; antibody-drug conjugates; ADC; CloakLink linker technology; solid tumors; oncology; SLV-154; SLV-324; clinical trials; venture capital; Yosemite; Merck

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

3 months ago talkbio0Tagged B-Cell Lymphomas, Business Update, Cancer Therapeutic Procedure, cash position, Clinical Trials, financial results, Immunome, net loss, pipeline update, Q3, RINGSIDE trial, therapeutic autologous dendritic cells, varegacestat

Immunome; Q3 2025; financial results; business update; pipeline update; cancer therapies; RINGSIDE trial; varegacestat; IM-1021; B-cell lymphoma; clinical trials; ADC; net loss; cash position

TScan Cuts Workforce by 30% While Iovance Advances Amtagvi Program Amid Layoffs

3 months ago talkbio0Tagged Amtagvi, Cell Therapy, Iovance Biotherapeutics, layoffs, Lymphocytes, Tumor-Infiltrating, Malignant neoplasm of lung, melanoma, strategic restructuring, TScan Therapeutics

TScan Therapeutics; layoffs; Iovance Biotherapeutics; Amtagvi; tumor-infiltrating lymphocyte (TIL) therapy; melanoma; lung cancer; strategic restructuring; biotech layoffs; cell therapy

Zag Bio Launches with $80M to Teach the Immune System to Make Better Tregs

3 months ago talkbio0Tagged AbbVie, Autoimmune Diseases, Diabetes Mellitus, Insulin-Dependent, Funding, Immune Tolerance, Regeneron, Regulatory T-Lymphocytes, sanofi, Series A, thymus-targeted therapy, Tregs, Zag Bio

Zag Bio; Tregs; regulatory T cells; autoimmune diseases; thymus-targeted therapy; Series A funding; immune tolerance; Type 1 diabetes; AbbVie; Regeneron; Sanofi

Gilead Cell Therapy Sales Drop 11% in Q3 2025, HIV Franchise Drives Growth

3 months ago talkbio0Tagged Biktarvy, cell therapy sales, financial results, Gilead Sciences, HIV franchise, Livdelzi, Q3, Tecartus, Trodelvy, Veklury, Yescarta, Yeztugo

Gilead Sciences; cell therapy sales; Q3 2025 financial results; HIV franchise; Yescarta; Tecartus; Biktarvy; Yeztugo; Livdelzi; Trodelvy; Veklury